Table 1. Baseline characteristics stratified per rs964184 genotype.
CC | CG | GG | |
(n = 4100) | (n = 1313) | (n = 134) | |
Age (years) | 60.0 ± 10.4 | 60.1 ± 10.3 | 61.0 ± 9.7 |
Male sex, n (%) | 3048 (74) | 982 (75) | 101 (75) |
BMI (kg/m2) | 26.8 ± 3.9 | 26.7 ± 4.0 | 27.1 ± 4.0 |
Total cholesterol (mmol/L) | 4.9 ± 1.2 | 5.0 ± 1.3 | 5.2 ± 1.3 |
Triglycerides (mmol/L) | 1.6 ± 1.0 | 1.9 ± 1.2 | 2.2 ± 1.3 |
LDL-c (mmol/L) | 3.0 ± 1.0 | 2.9 ± 1.1 | 3.0 ± 1.1 |
HDL-c (mmol/L) | 1.23 ± 0.37 | 1.20 ± 0.35 | 1.19 ± 0.31 |
Systolic blood pressure (mmHg) | 141 ± 21 | 141 ± 21 | 141 ± 21 |
Diastolic blood pressure (mmHg) | 82 ± 11 | 82 ± 11 | 81 ± 11 |
Metabolic Syndrome, n (%) | 2139 (52) | 718 (55) | 83 (62) |
Type 2 DM, n (%) | 686 (17) | 211 (16) | 29 (22) |
eGFR* (mL/min/1.73 m2) | 76 ± 18 | 76 ± 18 | 73 ± 19 |
Localisation of vascular disease, n (%): | |||
- coronary artery disease | 2449 (60) | 813 (62) | 86 (64) |
- cerebrovascular disease | 1198 (29) | 365 (28) | 34 (26) |
- peripheral artery disease | 824 (20 | 260 (20) | 31 (23) |
- aneurysm of abdominal aorta | 367 (9) | 119 (9) | 9 (7) |
Lipid-lowering medication, n (%) | 2596 (63) | 869 (66) | 90 (67) |
Antihypertensive medication, n (%) | 3003 (73) | 974 (74) | 105 (78) |
Current smoking, n (%) | 1383 (34) | 388 (30) | 43 (32) |
Current alcohol use, n (%) | 1993 (49) | 661 (50) | 61 (46) |
* Glomerular Filtration Rate, estimated by the Modification of Diet in Renal Disease (MDRD) equation.